Metabolic Profile of People Living with HIV in a Treatment Hub in Manila, Philippines: A Pre- and Post-Antiretroviral Analysis.

IF 0.6 Q4 ENDOCRINOLOGY & METABOLISM
Christian Francisco, Eddieson Gonzales, Marc Gregory Yu, Edsel Maurice Salvaña, Cybele Abad, Paul Ferdinand Reganit, Patricia Maningat, Olivia Sison, Marissa Alejandria
{"title":"Metabolic Profile of People Living with HIV in a Treatment Hub in Manila, Philippines: A Pre- and Post-Antiretroviral Analysis.","authors":"Christian Francisco, Eddieson Gonzales, Marc Gregory Yu, Edsel Maurice Salvaña, Cybele Abad, Paul Ferdinand Reganit, Patricia Maningat, Olivia Sison, Marissa Alejandria","doi":"10.15605/jafes.037.01.17","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>People living with HIV (PLHIV) are susceptible to develop dyslipidemia and hyperglycemia. This study aims to determine the prevalence of these metabolic derangements among Filipino PLHIV.</p><p><strong>Methodology: </strong>We reviewed 635 medical records in a treatment hub in Manila, Philippines from January 2004 to July 2016. Logistic regression analysis was done to determine factors associated with dyslipidemia and hyperglycemia pre- and post-ART.</p><p><strong>Results: </strong>Among 635 PLHIV, 97.3% were males with mean age of 30 years and median CD4 count of 207 cells/mm<sup>3</sup>. Pre-ART, prevalence of dyslipidemia was 65.4% and hyperglycemia was 10.4%. Risk factors for dyslipidemia include hyperglycemia (AOR 3.8, <i>p</i> 0.001) and >320 days delay in ART initiation from HIV confirmation (AOR 1.5, <i>p</i> 0.032), while dyslipidemia was associated with hyperglycemia (AOR 3.1, <i>p</i> 0.001). Post-ART, prevalence of dyslipidemia was 48.6% and hyperglycemia was 15.6%. Risk factors for post-ART dyslipidemia include being WHO stage 4 (AOR 2.1, <i>p</i> 0.021), hyperglycemia (AOR 16.1, <i>p</i><0.001), >36 months ART duration (AOR 8.7, <i>p</i><0.001) and efavirenz-based ART (AOR 2.8, <i>p</i><0.001). Low CD4 count post-ART had a negative correlation with dyslipidemia (AOR 0.5, <i>p</i> 0.005). Post-ART hyperglycemia was associated with age >30 years (AOR 2.1, <i>p</i> 0.004), being overweight (AOR 1.8, <i>p</i> 0.023), dyslipidemia (AOR 17.8, <i>p</i><0.001) and zidovudine-based ART (AOR 1.4, <i>p</i> 0.051).</p><p><strong>Conclusion: </strong>Dyslipidemia and hyperglycemia prevalence was high in Filipino PLHIV. Traditional, HIV and treatment related factors contributed to its development. Intensive monitoring and initiation of appropriate treatment is recommended.</p>","PeriodicalId":41792,"journal":{"name":"Journal of the ASEAN Federation of Endocrine Societies","volume":"37 1","pages":"53-61"},"PeriodicalIF":0.6000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/7f/JAFES-37-1-53.PMC9242666.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the ASEAN Federation of Endocrine Societies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15605/jafes.037.01.17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: People living with HIV (PLHIV) are susceptible to develop dyslipidemia and hyperglycemia. This study aims to determine the prevalence of these metabolic derangements among Filipino PLHIV.

Methodology: We reviewed 635 medical records in a treatment hub in Manila, Philippines from January 2004 to July 2016. Logistic regression analysis was done to determine factors associated with dyslipidemia and hyperglycemia pre- and post-ART.

Results: Among 635 PLHIV, 97.3% were males with mean age of 30 years and median CD4 count of 207 cells/mm3. Pre-ART, prevalence of dyslipidemia was 65.4% and hyperglycemia was 10.4%. Risk factors for dyslipidemia include hyperglycemia (AOR 3.8, p 0.001) and >320 days delay in ART initiation from HIV confirmation (AOR 1.5, p 0.032), while dyslipidemia was associated with hyperglycemia (AOR 3.1, p 0.001). Post-ART, prevalence of dyslipidemia was 48.6% and hyperglycemia was 15.6%. Risk factors for post-ART dyslipidemia include being WHO stage 4 (AOR 2.1, p 0.021), hyperglycemia (AOR 16.1, p<0.001), >36 months ART duration (AOR 8.7, p<0.001) and efavirenz-based ART (AOR 2.8, p<0.001). Low CD4 count post-ART had a negative correlation with dyslipidemia (AOR 0.5, p 0.005). Post-ART hyperglycemia was associated with age >30 years (AOR 2.1, p 0.004), being overweight (AOR 1.8, p 0.023), dyslipidemia (AOR 17.8, p<0.001) and zidovudine-based ART (AOR 1.4, p 0.051).

Conclusion: Dyslipidemia and hyperglycemia prevalence was high in Filipino PLHIV. Traditional, HIV and treatment related factors contributed to its development. Intensive monitoring and initiation of appropriate treatment is recommended.

Abstract Image

菲律宾马尼拉治疗中心艾滋病病毒感染者的代谢概况:抗逆转录病毒治疗前后的分析。
目的:艾滋病病毒感染者(PLHIV)容易出现血脂异常和高血糖。本研究旨在确定这些代谢紊乱在菲律宾艾滋病毒感染者中的发病率:我们查阅了菲律宾马尼拉一家治疗中心 2004 年 1 月至 2016 年 7 月期间的 635 份病历。结果:在 635 名 PLHIV 中,97% 的 PLHIV 在接受治疗后出现血脂异常和高血糖:在 635 名艾滋病毒感染者中,97.3% 为男性,平均年龄为 30 岁,CD4 细胞计数中位数为 207 cells/mm3。抗逆转录病毒治疗前,血脂异常发生率为 65.4%,高血糖发生率为 10.4%。血脂异常的危险因素包括高血糖(AOR 3.8,P 0.001)和从确认感染艾滋病病毒到开始接受抗逆转录病毒疗法的时间延迟大于 320 天(AOR 1.5,P 0.032),而血脂异常与高血糖有关(AOR 3.1,P 0.001)。ART 后,血脂异常发生率为 48.6%,高血糖发生率为 15.6%。导致抗逆转录病毒疗法后血脂异常的风险因素包括:WHO 4 期(AOR 2.1,P 0.021)、高血糖(AOR 16.1,P36)、抗逆转录病毒疗法持续时间(AOR 8.7,P0.005)。ART后高血糖与年龄大于30岁(AOR 2.1,p 0.004)、超重(AOR 1.8,p 0.023)、血脂异常(AOR 17.8,pp 0.051)有关:结论:菲律宾艾滋病毒感染者中血脂异常和高血糖的发病率很高。结论:菲律宾艾滋病毒感染者中血脂异常和高血糖的发病率很高,传统、艾滋病毒和治疗相关因素都是导致其发病的原因。建议加强监测并开始适当的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
22
审稿时长
8 weeks
期刊介绍: The Journal of the ASEAN Federation of Endocrine Societies (JAFES) is an OPEN ACCESS, internationally peer-reviewed, English language, medical and health science journal that is published in print two times a year by the ASEAN Federation of Endocrine Societies. It shall serve as the endocrine window between the ASEAN region and the world, featuring original papers and publishing key findings from specialists and experts of endocrinology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信